ESSA Pharma Company Overview
About ESSA Pharma
ESSA Pharma (NASDAQ:EPIX) is a biopharmaceutical entity focused on developing novel therapies for the treatment of prostate cancer. Its operations revolve around the research and development of small molecule drugs aimed at disrupting the androgen receptor signaling pathway, a critical target in the fight against this prevalent cancer. ESSA Pharma's projects include the advancement of its leading candidate, EPI-7386, through various stages of clinical trials with the goal of offering a new therapeutic option for patients with castration-resistant prostate cancer. The company's objectives are centered on bringing innovative treatments to market, addressing unmet medical needs, and improving the quality of life for individuals battling prostate cancer.
Snapshot
Operations
Products and/or services of ESSA Pharma
- EPI-7386, an oral small molecule inhibitor targeting the N-terminal domain of the androgen receptor for prostate cancer treatment.
- Preclinical programs exploring EPI-7386 in various combinations and treatment settings to expand its therapeutic potential.
- Research into novel N-terminal domain androgen receptor inhibitors to complement and diversify the treatment options for prostate cancer.
- Partnership efforts aimed at accelerating the development and commercialization of EPI-7386 and future candidates.
- Development of biomarker strategies to identify patients most likely to benefit from their therapies, enhancing precision medicine approaches.
ESSA Pharma executive team
- Mr. David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBAChief Financial Officer
- Nkengyal BarberExecutive
- Steve PondellExecutive
- Terry SchuenemeyerExecutive
- Dr. Roger Ulrich Ph.D.Consultant
- Dr. Jim BristolConsultant
- Ms. Kim HewittConsultant
- Dr. Stephen Plymate M.D.Consultant
- Kally SinghConsultant